Pediatric Studies for PPIs: Are Placebo-Controlled Trials In Infants Unethical?
Executive Summary
FDA is asking its pediatric advisory subcommittee to consider whether the agency's requirements for pediatric studies of proton pump inhibitors in infants under one year of age raise ethical concerns
You may also be interested in...
FDA Pediatric Therapeutics Office To Consider Ethics, Postmarket Safety
FDA is in the process of hiring an epidemiologist to coordinate epidemiology and safety reviews of approved pediatric products within the newly created Office of Pediatric Therapeutics
Abbott Will Outlicense Ketolide Antibiotic, Focus On Quinolone And D2E7
Abbott is seeking to outlicense its ketolide antibiotic ABT-773 in lieu of expanding Phase III development to address class issues
Abbott Will Outlicense Ketolide Antibiotic, Focus On Quinolone And D2E7
Abbott is seeking to outlicense its ketolide antibiotic ABT-773 in lieu of expanding Phase III development to address class issues